Pathologic expression of MHC class II is driven by mitogen‐activated protein kinases
Open Access
- 23 February 2007
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 37 (3) , 788-797
Abstract
The class II transactivator (CIITA) is the master regulator of MHC class II molecules (MHC II). In melanoma, the MHC II are constitutively expressed due to an abnormal transcription of CIITA from its promoter III (pIII), and requires the presence of a 1‐kb enhancer located upstream from this latter. Since mitogen‐activated protein kinases (MAPK) have been shown to be activated in most melanomas, we sought to analyze their possible involvement in CIITA expression. Using chemical inhibitors and dominant‐negative constructs of MAPK‐ERK kinase (Mek1) and MAPK‐JNK, we evidenced the inhibition of MHC II and CIITA expression in melanoma cell lines displaying activated MAPK. Transcriptional regulation by MAPK is known to involve the AP‐1 transcription factor family. Sequence analysis revealed an AP‐1‐responsive motif in the enhancer of CIITA pIII at –5954/–5947 from the site of transcription initiation. Its mutagenesis reduced CIITA expression four‐ to fivefold in melanoma cell lines and alleviated the effect of dominant‐negative constructs of the MAPK pathway. Together, our findings demonstrate that MAPK‐ERK and MAPK‐JNK are regulators of CIITA transcription in melanoma, and pinpoint an AP‐1‐responsive site in the CIITA gene pIII. This should have considerable impact on our understanding of the physio‐pathologic expression of MHC II.Keywords
This publication has 36 references indexed in Scilit:
- B-RAF and PI-3 kinase signaling protect melanoma cells from anoikisOncogene, 2006
- MHC II molecules in inflammatory diseases: interplay of qualities and quantitiesTrends in Immunology, 2005
- Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expressionImmunological Reviews, 2005
- HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cellsExperimental Cell Research, 2004
- AP-1: a double-edged sword in tumorigenesisNature Reviews Cancer, 2003
- Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) SignalingJournal of Biological Chemistry, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- MAP Kinases in the Immune ResponseAnnual Review of Immunology, 2002
- AP-1 function and regulationCurrent Opinion in Cell Biology, 1997
- DIFFERENT PATTERNS OF HLA‐DR ANTIGEN EXPRESSION IN NORMAL EPITHELIUM, HYPERPLASTIC AND NEOPLASTIC MALIGNANT LESIONS OF THE BREASTInternational Journal of Immunogenetics, 1995